Patients with severe chronic rhinosinusitis with nasal polyps experienced significant improvements in their symptoms with tezepelumab-ekko compared with placebo, according to a press release from ...

Tezepelumab (Tezspire) has shown significant clinical benefits in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), including marked reductions in nasal congestion and polyp ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp ...

WAYPOINT is a double-blind, multi-center, randomized, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of tezepelumab in adults with severe CRSwNP.1 ...

“The Waypoint results highlight the potential for tezepelumab as a new treatment option for patients with CRSwNP that has demonstrated rapid and sustained improvements in disease symptoms and ...

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire (tezepelumab-ekko) for treating chronic rhinosinusitis with nasal polyps (CRSwNP).

WAYPOINT was a double-blind, multi-centre, randomized, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of tezepelumab in adults with severe CRSwNP. 1,2,17 ...

Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.

THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE ...

Full results from the positive phase III WAYPOINT trial showed AstraZeneca and Amgen’s Tezspire (tezepelumab) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic ...

In patients with CRSwNP, TEZSPIRE had a safety profile consistent with its approved severe asthma indication. 1,2 The most frequently reported adverse events for TEZSPIRE in the WAYPOINT trial ...

WAYPOINT is a double-blind, multi-center, randomized, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of tezepelumab in adults with severe CRSwNP. 1,2,3 ...